Patent details

301257 Product Name: samenstelling welke omvat: cedazuridine of een farmaceutisch aanvaardbaar zout daarvan; en decitabine

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301257
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2207786
Status:
Application Pending
Application number:
301257
Procedural language:
Dutch
First Applicant Residence Country:
Japan (JP)

Marketing Authorization

Marketing Authorization Number:
EU/1/23/1756
Marketing Authorization Type:
EEA
Marketing Authorization Date:
18/09/2023
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
27/12/2023
First Marketing Authorization date:
18/09/2023
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
28/12/2023
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
27/12/2023
 
 

 

Name:
OTSUKA PHARMACEUTICAL CO., LTD.
Address:
2-9, Kanda Tsukasa-machi, Chiyoda-ku TOKYO 101-8535, Japan (JP)

Agent

1

Name:
ir. B.Ch. Ledeboer c.s
From:
09/01/2025
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:

2

Name:
ir. H.A. Witmans c.s.
From:
27/12/2023
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:
09/01/2025

Publication

Bulletin

Bulletin Heading:
SPC
Journal edition number:
01/24
Publication date:
03/01/2024
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
29/12/2023 Outgoing Correspondence Confirmation receipt request 2 PDF /1/3/9/7/5/0800957931/docs/301257_13_583278l174.pdf
27/12/2023 Application Form First filed application form 3 PDF /1/3/9/7/5/0800957931/docs/301257_0_applicationform20231228013929818.pdf
27/12/2023 SPC Documents Accompanying letter SPC 5 PDF /1/3/9/7/5/0800957931/docs/301257_1_supplprotectioncertificate20231228013929851.pdf
27/12/2023 SPC Documents Marketing Authorization SPC 3 PDF /1/3/9/7/5/0800957931/docs/301257_2_supplprotectioncertificate20231228013929877.pdf
27/12/2023 SPC Documents Marketing Authorization SPC 4 PDF /1/3/9/7/5/0800957931/docs/301257_3_supplprotectioncertificate20231228013929885.pdf
27/12/2023 SPC Documents Annex SPC 2 PDF /1/3/9/7/5/0800957931/docs/301257_4_supplprotectioncertificate20231228013929912.pdf
27/12/2023 SPC Documents Summary of the characteristics of the product 19 PDF /1/3/9/7/5/0800957931/docs/301257_5_supplprotectioncertificate20231228013929903.pdf
27/12/2023 SPC Documents Annex SPC 14 PDF /1/3/9/7/5/0800957931/docs/301257_6_supplprotectioncertificate20231228013929921.pdf
27/12/2023 SPC Documents Annex SPC 9 PDF /1/3/9/7/5/0800957931/docs/301257_7_supplprotectioncertificate20231228013929895.pdf
27/12/2023 SPC Documents Annex SPC 2 PDF /1/3/9/7/5/0800957931/docs/301257_8_supplprotectioncertificate20231228014652016.pdf
27/12/2023 SPC Documents Annex SPC 13 PDF /1/3/9/7/5/0800957931/docs/301257_9_supplprotectioncertificate20231228014652025.pdf
27/12/2023 SPC Documents Summary of the characteristics of the product 18 PDF /1/3/9/7/5/0800957931/docs/301257_10_supplprotectioncertificate20231228014651999.pdf
27/12/2023 SPC Documents Annex SPC 5 PDF /1/3/9/7/5/0800957931/docs/301257_11_supplprotectioncertificate20231228014652033.pdf
27/12/2023 SPC Documents Annex SPC 58 PDF /1/3/9/7/5/0800957931/docs/301257_12_supplprotectioncertificate20231228014652042.pdf